US biotech PureTech is to develop its most advanced pipeline drug LYT-100 as a potential treatment for inflammation and lung scarring in patients who have serious cases of COVID-19 or who h
The UK’s drugs regulator has said that there is enough evidence to support the use of Gilead’s COVID-19 drug remdesivir under its Early Access to Medicines Scheme (EAMS).